Latest News

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Pirtobrutinib

Andy Hawn, 2025 PharmD Candidate and Erin Kelley, PharmD, BCOP at the Masonic Cancer Clinic Infusion Pharmacy write about Pirtobrutinib

Tools and Resources Late Breaking News

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

Journal Club Journal Club

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Olutasidenib, with or without azacitidine, was well tolerated and showed meaningful clinical activity in patients with IDH1-mutated acute myeloid leukaemia.

Education

Overcoming Challenges to Provide BiTE and CAR T Cell Therapy at a Community Cancer Center

Feature Story

Pharmacists talking
Education

Reaching the Melting Point: My Time Transitioning from a Solid to a Liquid Tumor Pharmacist

Reflection on Personal Impact and Growth

Imaging scan of lung cancer
Tools and Resources Drug Updates

Pharmacist Application to Practice: Adagrasib

Sam Palmatier, Pharmacy Intern and Jeff Engle, PharmD, MS, Oncology Pharmacy Manager at Fairview Cancer Clinic – Edina write about

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Mosunetuzumab

Bernard Marini, PharmD, BCOP Clinical Pharmacist Specialist – Hematology/Oncology Clinical Associate Professor University of Michigan College of Pharmacy writes about Mosunetuzumab.

Drug Updates

Pharmacist's Application to Practice: Nadofaragene
firadenovec-vncg

Kelli Rourke, PharmD Clinical Pharmacy Specialist at The Johns Hopkins Hospital writes about nadofaragene firadenovec-vncg

Pharmacist's Application to Practice: Olutasidenib

Bernard Marini, PharmD, BCOP, Clinical Pharmacist at University of Michigan College of Pharmacy writes about Olutasidenib

Drug Updates

Pharmacist’s Application to Practice:
Mirvetuximab soravtansine-gynx

Shrina Patel, PharmD, BCOP, Clinical Pharmacy Specialist at University of Texas MD Anderson Cancer Center writes about Mirvetuximab soravtansine-gynx.

Scan of human lungs
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Tremelimumab

Tremelimumab (IMJUDO, AztraZeneca Pharmaceuticals) approved November 10, 2022 for metastatic non-small cell lung cancer and approved October 24, 2022 for unresectable hepatocellular carcinoma

Tools and Resources Drug Updates

Pharmacist’s Application to Practice: Teclistamab-cqyv

Gavyn Walsh, PD3 Oncology Pharmacy Intern and Erin Kelley, PharmD, BCOP at M Health Fairview Masonic Cancer Clinic write about teclistamab-cqyv